Secondary Logo

Journal Logo

Salt sensitivity: a consequence of the metabolic syndrome?

Melander, Olle

doi: 10.1097/01.hjh.0000239280.89819.bc
Editorial commentaries

Department of Clinical Sciences, Clinical Research Unit of Medicine and Clinical Research Center, Lund University, Malmö University Hospital, Malmö, Sweden

Correspondence and requests for reprints to Olle Melander, Clinical Research Center, Entrance 72, Building 91, Floor 12, Malmö University Hospital, SE-205 02 Malmö, Sweden Tel: +46 40 391209; fax: +46 40 391222; e-mail:

Back to Top | Article Outline

Inter-relationships between the metabolic syndrome, insulin resistance and salt-sensitive hypertension

The metabolic syndrome, namely the clustering of disturbances in glucose metabolism, dyslipidaemia, central obesity and essential hypertension, is a powerful predictor of cardiovascular disease [1–3]. Although there are several different definitions of the metabolic syndrome, hypertension is included in all [4–7]. The cause of the metabolic syndrome is largely unknown, although insulin resistance has been suggested to be a common link between its individual components [8]. The pathophysiological relationship between hypertension and the other more classically metabolic traits of the syndrome seems particularly intriguing, and new knowledge in this field may be of great importance for the understanding and treatment of essential hypertension.

Reduced salt intake lowers blood pressure, although the magnitude of the reduction in the general population is widely debated [9–11]. It is well established that salt sensitivity, namely the individual blood pressure-lowering effect of reduced salt intake, varies between individuals. Hypertensive patients are more salt sensitive than normotensive individuals [12], and normotensive individuals with heredity for hypertension are more salt sensitive than those without such a family history [13,14], suggesting that salt sensitivity is part of the inherited predisposition of essential hypertension. Interestingly, insulin resistance is also associated with a family history of hypertension in normotensive individuals [15], raising the question of whether salt sensitivity and insulin resistance are related hypertension-associated traits. Both normotensive and hypertensive salt-sensitive individuals have been shown to be hyperinsulinaemic [16,17], insulin resistant [18–20], or both when compared with salt-resistant individuals; however, the finding has not been universal [21]. Considering the central role of insulin resistance in the metabolic syndrome, it is possible that the syndrome is linked to salt-sensitive hypertension. In the present issue of the journal, Uzu and co-workers [22] report associations between the presence of the metabolic syndrome and salt-sensitive hypertension. Furthermore, central obesity, the core criterion for the metabolic syndrome according to the definition proposed by the International Diabetes Federation [4], was independently associated with salt sensitivity [22].

Back to Top | Article Outline

Potential molecular mechanisms linking the metabolic syndrome with hypertension and salt sensitivity

Blood pressure and hypertension are highly heritable traits [23,24], but the normal distribution of blood pressure at the population level suggests a polygenic and multifactorial aetiology in the majority of hypertensive patients. Interestingly, a number of salt-sensitive monogenic forms of hypertension have been explained at the molecular level. The mutations causing these disorders directly or indirectly lead to the over-expression of either the amiloride-sensitive epithelial sodium channel (ENaC) or the thiazide-sensitive NaCl co-transporter expressed in the distal nephron [25–30]. One of the first monogenic forms of hypertension to be explained at the molecular genetic level, Liddle's syndrome, is caused by mutations in the C-terminus of ENaC [25]. Normally, the protein neuronal precursor cell expressed developmentally downregulated 4-like (NEDD4L) removes ENaC from the tubular apical cell surface in the renal collecting ducts by binding to the C-terminus of ENaC [31,32], thereby keeping ENaC expression at a controlled level. The ENaC mutations in Liddle's syndrome delete or alter the ENaC C-terminus, leading to inhibiton of the NEDD4L–ENaC interaction. This results in over-expression of ENaC, renal hyper-reabsorption of sodium and salt-sensitive hypertension.

Although Liddle's syndrome patients do not typically display a metabolic syndrome phenotype, and hypertension-causing ENaC mutations are rare [33], these findings contributed to the discovery of a new signalling pathway that could be a central link between salt-sensitive hypertension and the metabolic syndrome. The ENaC channel remover NEDD4L is regulated by the serum and glucocorticoid regulated kinase 1 (SGK1), which in turn is regulated by the renin–angiotensin–aldosterone system and by insulin [34]. Aldosterone bound to the mineralocorticoid receptor binds to the SGK1 promoter and drives up SGK1 expression, whereas insulin, via its effects on phosphatidylinositol-3-kinase, activates SGK1 through phosphorylation. The activation of SGK1 by insulin as well as increased SGK1 expression by aldosterone thus inhibits NEDD4L to remove ENaC from the renal tubular cells, which in turn would be expected to cause increased renal sodium reabsorption and salt sensitivity.

Peripheral insulin resistance and its close companion of central obesity lead to compensatory hyperinsulinaemia. Importantly, although the muscle is resistant to insulin-mediated glucose uptake in insulin-resistant states, such as in hypertension and in normotensive individuals with a positive family history of hypertension, the sodium-retaining effect of insulin at the level of the kidney is maintained at normal [35,36]. The compensatory hyperinsulinaemia seen in the metabolic syndrome could thus be speculated to cause salt-sensitive hypertension through increased load on the SGK1–NEDD4L–ENaC interaction. Interestingly, common genetic variance of SGK1 leads to higher blood pressure at the population level [37]. Although the fasting plasma concentration of insulin is positively correlated with blood pressure regardless of genetic variants of SGK1, individuals carrying the blood pressure-elevating variants of the SGK1 gene had a significantly stronger correlation between the fasting plasma concentration of insulin and diastolic blood pressure than did those who did not carry these genetic variants [37]. Again, this suggests that the interaction between insulin and SGK1 may elevate blood pressure and the risk of hypertension through increased EnaC-mediated renal sodium reabsorption.

Back to Top | Article Outline

Implications for treatment of hypertension in the metabolic syndrome

The findings by Uzu et al. [22], suggesting an association between salt-sensitive hypertension and the metabolic syndrome, together with recent studies highlighting the role of the insulin–SGK1–NEDD4L–ENaC system [34], may have relevance for the treatment of hypertension in the metabolic syndrome. Interventions specifically targeted at the insulin–SGK1–NEDD4L–ENaC system would seem attractive. This may include interventions lowering circulating insulin concentrations as can be achieved by improving peripheral insulin sensitivity. The blood pressure-lowering effect of physical exercise and insulin-sensitizing drugs, such as thiazolidinediones [38], could thus be mediated through decreased load on the insulin–SGK1–NEDD4L–ENaC system. Furthermore, dietary salt restriction should be included as first-line life-style therapy for the metabolic syndrome together with physical exercise. The findings also encourage new studies on the antihypertensive and cardioprotective effects of amiloride as well as on the development of specific SGK1 inhibitors and NEDD4L enhancers in the treatment of hypertension in the metabolic syndrome.

The proposed relationship between the metabolic syndrome and salt-sensitive hypertension needs to be confirmed in other studies. Furthermore, although likely to be the case, it is still not entirely clear whether the metabolic syndrome adds predictive value for cardiovascular disease independently of classical cardiovascular risk factors, and whether the different definitions of the syndrome predict cardiovascular disease equally well. The exact role of the newly discovered insulin–SGK1–NEDD4L–ENaC system in the pathogenesis of salt-sensitive hypertension in the metabolic syndrome and its clinical relevance remains to be shown. However, the potential links between the metabolic syndrome, salt-sensitive hypertension and the insulin–SGK1–NEDD4L–ENaC system is definitely a promising and refreshing research field for the next few years.

Back to Top | Article Outline


1 Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93:136–141.
2 Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110:1245–1250.
3 Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288:2709–2716.
4 Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366:1059–1062.
5 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497.
6 Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15:539–553.
7 Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16:442–443.
8 Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595–1607.
9 Graudal NA, Galloe AM, Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-analysis. JAMA 1998; 279:1383–1391.
10 He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens 2002; 16:761–770.
11 Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH–Sodium Collaborative Research Group. N Engl J Med 2001; 344:3–10.
12 Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension 1986; 8:II127–II134.
13 Sharma AM, Schorr U. Salt sensitivity and insulin resistance: is there a link? Blood Press Suppl 1996; 5:59–63.
14 Skrabal F, Hamberger L, Ledochowski M. Inherited salt sensitivity in normotensive humans as a cause of essential hypertension: a new concept. J Cardiovasc Pharmacol 1984; 6(Suppl. 1):S215–S223.
15 Endre T, Mattiasson I, Hulthén UL, Lindgärde F, Berglund G. Insulin resistance is coupled to low physical fitness in normotensive men with a family history of hypertension. J Hypertens 1994; 12:81–88.
16 Zavaroni I, Coruzzi P, Bonini L, Mossini GL, Musiari L, Gasparini V, et al. Association between salt sensitivity and insulin concentrations in patients with hypertension. Am J Hypertens 1995; 8:855–858.
17 Sharma AM, Ruland K, Spies KP, Distler A. Salt sensitivity in young normotensive subjects is associated with a hyperinsulinemic response to oral glucose. J Hypertens 1991; 9:329–335.
18 Sharma AM, Schorr U, Distler A. Insulin resistance in young salt-sensitive normotensive subjects. Hypertension 1993; 21:273–279.
19 Fuenmayor N, Moreira E, Cubeddu LX. Salt sensitivity is associated with insulin resistance in essential hypertension. Am J Hypertens 1998; 4:397–402.
20 Galletti F, Strazzullo P, Ferrara I, Annuzzi G, Rivellese AA, Gatto S, et al. NaCl sensitivity of essential hypertensive patients is related to insulin resistance. J Hypertens 1997; 15:1485–1491.
21 Melander O, Groop L, Hulthen UL. The effect of salt on insulin sensitivity differs according to gender and degree of salt sensitivity. Hypertension 2000; 35:827–831.
22 Uzu T, Kimura G, Yamauchi A, Kanasaki M, Isshiki K, Araki S, et al. Enhanced sodium sensitivity and disturbed circadian rhythm of blood pressure in essential hypertensive patients with metabolic syndrome. J Hypertens 2006; 24:1626–1632.
23 Fava C, Burri P, Almgren P, Groop L, Hulthen UL, Melander O. Heritability of ambulatory and office blood pressure phenotypes in Swedish families. J Hypertens 2004; 22:1717–1721.
24 Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. J Chronic Dis 1986; 39:809–821.
25 Shimkets RA, Warnock DG, Bositis CM, Nelson Williams C, Hansson JH, Schambelan M, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994; 79:407–414.
26 Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet 1995; 10:394–399.
27 Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355:262–265.
28 Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289:119–123.
29 Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, et al. Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci U S A 2003; 100:680–684.
30 Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, et al. Human hypertension caused by mutations in WNK kinases. Science 2001; 293:1107–1112.
31 Harvey KF, Dinudom A, Cook DI, Kumar S. The Nedd4-like protein KIAA0439 is a potential regulator of the epithelial sodium channel. J Biol Chem 2001; 276:8597–8601.
32 Kamynina E, Debonneville C, Bens M, Vandewalle A, Staub O. A novel mouse Nedd4 protein suppresses the activity of the epithelial Na+ channel. FASEB J 2001; 15:204–214.
33 Melander O, Orho M, Fagerudd J, Bengtsson K, Groop PH, Mattiasson I, et al. Mutations and variants of the epithelial sodium channel gene in Liddle's syndrome and primary hypertension. Hypertension 1998; 31:1118–1124.
34 Pearce D. The role of SGK1 in hormone-regulated sodium transport. Trends Endocrinol Metab 2001; 12:341–347.
35 Endre T, Mattiasson I, Berglund G, Hulthen UL. Insulin and renal sodium retention in hypertension-prone men. Hypertension 1994; 23:313–319.
36 Reaven GM. The kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis 1997; 30:928–931.
37 von Wowern F, Berglund G, Carlson J, Mansson H, Hedblad B, Melander O. Genetic variance of SGK-1 is associated with blood pressure, blood pressure change over time and strength of the insulin-diastolic blood pressure relationship. Kidney Int 2005; 68:2164–2172.
38 Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279–1289.
© 2006 Lippincott Williams & Wilkins, Inc.